These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1422609)

  • 21. Return of sense of taste with fluphenazine.
    Clovis WL
    J Neuropsychiatry Clin Neurosci; 1989; 1(3):339-40. PubMed ID: 2521079
    [No Abstract]   [Full Text] [Related]  

  • 22. Life events, relatives' expressed emotion and maintenance neuroleptics in schizophrenic relapse.
    Leff J; Kuipers L; Berkowitz R; Vaughn C; Sturgeon D
    Psychol Med; 1983 Nov; 13(4):799-806. PubMed ID: 6141582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study.
    Hogarty GE; McEvoy JP; Munetz M; DiBarry AL; Bartone P; Cather R; Cooley SJ; Ulrich RF; Carter M; Madonia MJ
    Arch Gen Psychiatry; 1988 Sep; 45(9):797-805. PubMed ID: 3415422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A one year prospective study of the effect of life events and medication in the aetiology of schizophrenic relapse.
    Hirsch S; Bowen J; Emami J; Cramer P; Jolley A; Haw C; Dickinson M
    Br J Psychiatry; 1996 Jan; 168(1):49-56. PubMed ID: 8770428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Depot neuroleptics: the relevance of psychosocial factors--a United States perspective.
    Hogarty GE
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):36-42. PubMed ID: 6143746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone.
    Weiden PJ; Kim E; Bermak J; Turkoz I; Gopal S; Berwaerts J
    J Clin Psychiatry; 2017 Jul; 78(7):e813-e820. PubMed ID: 28640988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relapse rate and low serum neuroleptic levels in schizophrenics treated with fluphenazine: another view.
    Boza RA; Milanes F; Starkey T; Slater V; Dominguez F
    J Clin Psychiatry; 1988 Jun; 49(6):245. PubMed ID: 2897960
    [No Abstract]   [Full Text] [Related]  

  • 28. Psychosocial relevance and benefit of neuroleptic maintenance: experience in the United Kingdom.
    Leff J; Kuipers L; Berkowitz R; Eberlein-Fries R; Sturgeon D
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):43-9. PubMed ID: 6143747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective study of stressful life events and schizophrenic relapse.
    Ventura J; Nuechterlein KH; Lukoff D; Hardesty JP
    J Abnorm Psychol; 1989 Nov; 98(4):407-11. PubMed ID: 2592674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks.
    Carpenter WT; Buchanan RW; Kirkpatrick B; Lann HD; Breier AF; Summerfelt AT
    Am J Psychiatry; 1999 Mar; 156(3):412-8. PubMed ID: 10080557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cocaine use by schizophrenic outpatients who receive depot neuroleptic medication.
    Stone AM; Greenstein RA; Gamble G; McLellan AT
    Hosp Community Psychiatry; 1993 Feb; 44(2):176-7. PubMed ID: 8432504
    [No Abstract]   [Full Text] [Related]  

  • 32. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
    Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
    Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilities.
    Asarnow RF; Marder SR; Mintz J; Van Putten T; Zimmerman KE
    Arch Gen Psychiatry; 1988 Sep; 45(9):822-6. PubMed ID: 3046554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychotic symptoms preceding ocular deviation in a patient with tardive oculogyric crises.
    Sachdev P; Tang WM
    Aust N Z J Psychiatry; 1992 Dec; 26(4):666-70. PubMed ID: 1362053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication.
    Glazer WM; Morgenstern H; Schooler N; Berkman CS; Moore DC
    Br J Psychiatry; 1990 Oct; 157():585-92. PubMed ID: 1983390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
    Chouinard G; Annable L; Ross-Chouinard A
    Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
    [No Abstract]   [Full Text] [Related]  

  • 37. Factors affecting rehospitalisation rates of chronic schizophrenic patients living in the community.
    Soni SD; Gaskell K; Reed P
    Schizophr Res; 1994 May; 12(2):169-77. PubMed ID: 8043527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.
    Mayoral-van Son J; de la Foz VO; Martinez-Garcia O; Moreno T; Parrilla-Escobar M; Valdizan EM; Crespo-Facorro B
    J Clin Psychiatry; 2016 Apr; 77(4):492-500. PubMed ID: 26759992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
    Brown WA; Silver MA
    J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antipsychotic medication: clinical guidelines for maintenance therapy.
    Johnson DA
    J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.